{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:52:07Z","timestamp":1791359527636,"version":"4.3.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fecal incontinence (FI) is prevalent in critically ill oncology patients, frequently compounded by chemotherapy-induced diarrhea (CID) and severe thrombocytopenia. Conventional indwelling balloon catheters (IBCs), the standard approach to FI management in the ICU, generate intraluminal radial pressures that frequently exceed mucosal capillary perfusion thresholds and are formally contraindicated by manufacturers in patients with platelet counts below 50 x 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L. This retrospective analysis and structured narrative literature review evaluates the safety, fecal containment efficacy, and nursing workload impact of a novel pressure-free automated stool management (ASM) system in high-risk oncology ICU patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted at a major academic comprehensive cancer center in the United States during 2025. Outcome data from 190 unique adult oncology ICU patients, including two structured evaluation cohorts of 20 patients each, followed by broader institutional implementation (n=150), were compiled from standardized nursing quality improvement product evaluation forms completed throughout each patient\u2019s device-use period. A prospectively designated thrombocytopenic subgroup (n=47; platelet counts &amp;lt;50 x 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L at device deployment) was analyzed separately. A structured narrative literature review was conducted across PubMed, MEDLINE, and CINAHL (final search: February 2026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across 190 unique device placements, zero device-related adverse events were observed (adverse event rate 0%; 95% CI upper bound 1.6%, rule of three). In the thrombocytopenic subgroup (n=47), zero device-related adverse events were observed (95% CI upper bound 6.4%). No device-related mucosal bleeding, perforation, ulceration, necrosis, or device malfunction requiring intervention was documented. The device achieved 100% successful fecal diversion, with no major leakage event (defined as stool output requiring linen replacement) recorded. The per-assessment leakage rate was 1.7% (11 positive assessments out of 646 total), all representing minor peripheral moisture requiring only topical hygiene management with no linen change. Daily nursing time with ASM was 6.8 minutes per patient per day; contextual comparison with published estimates of 120 minutes per patient per day (IBC protocol) and 174 minutes per patient per day (absorbent pad management) from Vargo et\u00a0al. yields estimated differences of 94% and 96%, respectively, subject to methodological differences between datasets. Retrospective chart review identified no chemotherapy delays or ICU length of stay prolongation attributable to device-related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This early institutional experience with a novel pressure-free ASM across 190 unique oncology ICU placements, including 47 in patients with severe thrombocytopenia, was not associated with any observed device-related adverse event. These findings represent hypothesis-generating preliminary data and do not establish superiority over conventional devices. The clinical need for safe fecal management alternatives in thrombocytopenic oncology patients is substantive; these data provide rationale for appropriately powered prospective comparative trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1895799","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:46Z","timestamp":1791357286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early clinical experience with a novel automated fecal management system for fecal incontinence in high-risk oncology and intensive care unit patients: a retrospective analysis and structured narrative literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Karen Lou","family":"Kennedy-Evans","sequence":"first","affiliation":[{"name":"Independent Researcher","place":["Tucson, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Vargo","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Cuyahoga Falls, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","volume-title":"Aha Hospital Statistics 2024","year":"2024"},{"key":"B2","volume-title":"Critical Care Statistics","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-200003000-00007","article-title":"Fecal incontinence in hospitalized patients who are mobile","volume":"100","author":"Bliss","year":"2000","journal-title":"Am J Nurs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2823","article-title":"Clinical epidemiology of fecal incontinence in hospitalized patients","volume":"12","author":"Fikry","year":"2017","journal-title":"J Hosp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030923","article-title":"5-fluorouracil-induced diarrhea: Focus on pathophysiology and pharmacological management","volume":"15","author":"Zilli","year":"2023","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.1312","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.02.840","article-title":"TRIBUTE: A phase III trial of erlotinib hydrochloride combined with carboplatin and paclitaxel in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2011.03.007","article-title":"Pelvic radiation disease","volume":"202","author":"Chen","year":"2011","journal-title":"Am J Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/m14-1589","article-title":"Platelet transfusion: A clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Internal Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc2010780","article-title":"Pressures generated by indwelling rectal catheter systems","volume":"19","author":"Sparks","year":"2010","journal-title":"Am J Crit Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004206","article-title":"Quantifying the clinical risk of indwelling fecal catheters in critically ill patients","volume":"48","author":"Keshava","year":"2020","journal-title":"Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.won.0000270820.91694.1f","article-title":"Prevalence of incontinence and associated skin injury in the acute care setting","volume":"34","author":"Junkin","year":"2007","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000359537.14877.1c","article-title":"Incidence of fecal incontinence: Measurement methods and clinical significance","volume":"22","author":"Doughty","year":"2009","journal-title":"Adv Skin Wound Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182741e91","article-title":"Clinical outcomes associated with use of an indwelling rectal catheter in patients with severe thrombocytopenia","volume":"41","author":"Pittman","year":"2013","journal-title":"Crit Care Med"},{"key":"B18","unstructured":"Sphincter Damage Due to Intrarectal Balloon Catheter Use in the ICU\n          \n          2024"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767110-00009","article-title":"Octreotide long-acting release: In patients with chemotherapy-induced diarrhea","volume":"67","author":"Curran","year":"2007","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistic","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B21","volume-title":"ISO 10993-1:2018 Biological Evaluation of Medical Devices","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1761399","article-title":"Evolution and economic evaluation of fecal incontinence management in United States intensive care units: From historical containment to automated diversion","volume":"13","author":"Vargo","year":"2026","journal-title":"Front Med"},{"key":"B24","unstructured":"Occupational Employment and Wage Statistics: Registered Nurses (SOC 29-1141)\n          \n          2023"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2006.00803.x","article-title":"Pelvic floor: Anatomy and physiology","volume":"18","author":"Bharucha","year":"2006","journal-title":"Neurogastroenterol Motil"},{"key":"B26","article-title":"High prevalence of anal incontinence in patients with insulin-dependent diabetes mellitus","volume":"37","author":"Moesgaard","year":"1994","journal-title":"Dis Colon Rectum"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0285-6","article-title":"Irinotecan: A review of its use in colorectal cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1124\/pr.123.000971","article-title":"Mechanisms and emerging strategies for irinotecan-induced diarrhea","volume":"76","author":"Xu","year":"2024","journal-title":"Pharmacol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0301-y","article-title":"Managing toxicities associated with immunotherapy: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05573-4","article-title":"Epidemiology, causes and complications of fecal incontinence in hospitalized patients","volume":"64","author":"Gatta","year":"2019","journal-title":"Digestive Dis Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jcrc.2011.09.010","article-title":"Iatrogenic rectal perforation in a patient on anticoagulation secondary to indwelling fecal catheter use","volume":"27","author":"Padmanabhan","year":"2012","journal-title":"J Crit Care"},{"key":"B35","unstructured":"Indwelling Fecal Catheter and Balloon Catheter Adverse Events"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/s0195-6701(07)60002-4","article-title":"Epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England","volume":"65","author":"Pratt","year":"2007","journal-title":"J Hosp Infection"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/657912","article-title":"Estimating the proportion of hospital-acquired infections that are reasonably preventable and the related mortality and costs","volume":"32","author":"Umscheid","year":"2011","journal-title":"Infection Control Hosp Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4037\/ccn2016543","article-title":"AACN practice alert: Prevention of infection in critically ill patients","volume":"36","year":"2016","journal-title":"Crit Care Nurse"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B40","article-title":"Chemotherapy-induced diarrhea in colorectal cancer","volume":"23","author":"Chu","year":"1996","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B41","article-title":"Chemotherapy dose reductions due to chemotherapy-induced diarrhea: A critical appraisal","volume":"12","author":"Dranitsaris","year":"2005","journal-title":"Curr Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:50Z","timestamp":1791357290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1895799"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895799","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1895799"}}